Use of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents  by Hongo, Richard H. et al.
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OBJECTIVES We sought to assess the efficacy and safety of ibutilide cardioversion for those with atrial
fibrillation (AF) or atrial flutter (AFL) receiving long-term treatment with class IC agents.
BACKGROUND Attenuation of ibutilide-induced QT prolongation has been observed in a small number of
patients pretreated with class IC agents. The clinical significance of the interaction between
ibutilide and class IC agents is unknown.
METHODS Seventy-one patients with AF (n  48) or AFL (n  23), receiving propafenone 300 to 900
mg/day (n  46) or flecainide 100 to 300 mg/day (n  25), presented for ibutilide (2.0 mg)
cardioversion.
RESULTS The mean durations of arrhythmia episode and arrhythmia history were 25 48 days and 4.4
 6.4 years, respectively. Sixty-five patients (91.5%) had normal left ventricular systolic
function. Twenty-three of 48 patients (47.9%; 95% confidence interval, 33.3% to 62.8%) with
AF and 17 of 23 patients (73.9%; 95% confidence interval, 51.6% to 89.8%) with AFL
converted with mean conversion times of 25  14 min and 20  12 min, respectively. There
was a small increase in corrected QT interval after ibutilide (from 442  61 ms to 462  59
ms, p  0.006). One patient developed non-sustained polymorphous ventricular tachycardia
and responded to intravenous magnesium. Another developed sustained torsade de pointes
and was treated effectively with direct-current shock and intravenous dopamine.
CONCLUSIONS Our observations suggest that the use of ibutilide in patients receiving class IC agents is as
successful in restoring sinus rhythm and has a similar incidence of adverse effects as the use
of ibutilide alone. (J Am Coll Cardiol 2004;44:864–8) © 2004 by the American College of
Cardiology Foundation(
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(lass IC antiarrhythmic agents are frequently used in the
anagement of patients with atrial fibrillation (AF) or atrial
utter (AFL) and are recommended as first-line antiar-
hythmic therapy of AF in patients with no or minimal
eart disease (1). At times, the use of these agents in
atients with AF may result in the induction of AFL, or
o-called IC flutter (2). Despite the use of catheter ablation
o treat AF and AFL in selected patients, recurrences of
hese arrhythmias and the development of IC flutter are
ommon experiences, and the evaluation of cardioversion
echniques is appropriate.
Ibutilide has been found in comparative studies to be the
ost effective intravenous agent for conversion of AF and
FL (3–5). In the only reported study that has specifically
valuated the interaction of ibutilide with class IC agents,
eiffel et al. (6) found that pretreatment with either
ropafenone or flecainide in six patients attenuated
butilide-induced corrected QT (QTC) interval prolonga-
ion without altering ibutilide efficacy. Ibutilide has been
ound to both block the delayed rectifier potassium current
From the *University of California, San Francisco, San Francisco, California;
Umberto I Hospital, Mestre-Venice, Italy; and ‡University of California, Davis,
avis, California. Dr. Scheinman is on the speaker bureau for 3M (maker of
ecainide).
Manuscript received March 30, 2004; revised manuscript received May 5, 2004,ccepted May 11, 2004.7) and enhance the slow inward sodium current (INa) (8),
nd it is thought to exert its class III antiarrhythmic effect by
ne or both mechanisms. Class IC agents primarily block
ast INa, may conceivably curtail the degree of prolongation
n action potential duration caused by the enhancement of
low INa by ibutilide, and may consequently decrease the
ncidence of adverse effects and/or efficacy of ibutilide. The
urpose of our study was to assess the efficacy and safety of
butilide cardioversion for those with AF or AFL receiving
ong-term treatment with class IC agents.
ETHODS
atients. Seventy-one consecutive patients, receiving ei-
her propafenone or flecainide for treatment of AF or AFL,
resented for elective cardioversion of either AF or AFL.
atients were recruited from two centers (University of
alifornia, San Francisco, and Umberto I Hospital, Mestre-
enice, Italy) and were evaluated prospectively. Patients
ere excluded if they were 18 years of age, of child-
earing potential, or receiving an antiarrhythmic agent other
han a class IC agent. Patients were also excluded if they had
previous episode of torsade de pointes, a QTC interval
500 ms, a systolic blood pressure 90 mm Hg, a heart
ate 60 beats/min, a left ventricular (LV) ejection fraction
EF) 40%, or evidence of active ischemic heart disease.Ventricular rate control was permitted with beta-blocker,
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August 18, 2004:864–8 Cardioversion With Ibutilide and Class IC Agentsalcium-channel blocker, or digoxin. Left ventricular systolic
unction was assessed by echocardiography; LVEF50% was
onsidered normal. Anticoagulation therapy was instituted
efore cardioversion if the duration of arrhythmia was 48 h.
hen clinically indicated, a transesophageal echocardiography
as performed to exclude intracardiac thrombus. The duration
f arrhythmia was measured in days, from recognition of
ersistent arrhythmia to cardioversion. A duration 24 h was
ounted as one day for purposes of analysis. Serum potassium
nd magnesium levels were assessed before cardioversion, and
lectrolytes were supplemented if the potassium level was4.0
mol/l or the magnesium level was1.6 mmol/l. Patients did
ot receive magnesium prophylactically. The institutional re-
iew board from each center approved the study, and informed
onsents were obtained from the participating patients.
ardioversion protocol. Cardioversions were performed
n a cardiac electrophysiology laboratory or an intensive care
nit capable of continuous electrocardiographic (ECG)
onitoring. External cardioverter defibrillator pads were
laced in anterior-posterior configuration and were con-
ected to a direct-current cardioverter defibrillator unit.
Abbreviations and Acronyms
AF  atrial fibrillation
AFL  atrial flutter
CI  confidence interval
ECG  electrocardiogram/electrocardiographic
EF  ejection fraction
IKr  delayed rectifier potassium current
INa  sodium current
LV  left ventricle/ventricular
QTC  corrected QT (interval)
SR  sinus rhythm
igure 1. Assessment of QT interval during atrial arrhythmia and sinus r
larified by comparing it with the end of the QT interval in sinus rhythm (*)
s clarified by comparing it with the end of the QT interval in sinus rhythm (*)ne milligram of ibutilide (Pharmacia & Upjohn Co.,
alamazoo, Michigan) was infused intravenously through a
eripheral vein over 10 min. This was followed by a 10-min
bservation period. If patients did not convert to sinus
hythm (SR) by the end of the observation period, an
dditional 1 mg was administered over 10 min. Infusion was
topped for termination of arrhythmia, development of
ysrhythmia, or QT-interval prolongation 600 ms. If
atients did not convert to SR after completion of the
econd infusion, conventional synchronized direct-current
ardioversion was performed within 30 min (within 60 min
f ibutilide initiation). It was recognized that while this was
relatively short post-ibutilide (to direct-current shock)
eriod, pressures of laboratory and intensive care unit
tilization made this compromise necessary. When possible,
owever, patients were observed a full 1 h from time of
butilide initiation before proceeding with direct-current
ardioversion. All patients were observed with continuous
CG monitoring for 4 h after ibutilide infusion.
CG measurements. A 12-lead ECG was obtained before
butilide infusion (during arrhythmia) and after cardiover-
ion (during SR). Electrocardiograms were recorded at 25
m/s paper-speed, and the QT interval was assessed in
eads without U waves. The QT interval was measured from
he initiation of the QRS complex to the intersection of the
-wave downslope extension and the baseline. When the
T interval during atrial arrhythmia was difficult to ascer-
ain because of fibrillatory or flutter waves, the QT interval
fter conversion to SR was used to help clarify the end of the
T interval (Fig. 1). The RR interval was measured as the
istance between two consecutive R-wave peaks. In patients
ith AF, we measured RR and QT intervals from five
onsecutive beats. The mean RR interval and the longest
. (A) The end of the QT interval (diamond) during atrial fibrillation is
conversion. (B) The end of the QT interval (diamond) during atrial flutterhythm
afterafter conversion.
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logists, one who was kept unaware of the study protocol
Y.Y.), independently read 20 randomly selected ECGs in
rder to assess the reproducibility of QT measurement. The
ntra- and inter-observer Pearson’s correlation coefficients of
he measured QT interval during atrial arrhythmia were
.972 and 0.967, respectively. The intra- and inter-observer
orrelation coefficients of the measured QT interval after
onversion to SR were 0.968 and 0.970, respectively. The
TC interval was calculated using Bazett’s formula.
tatistical analysis. Continuous variables were expressed
s mean  SD and were analyzed using the Student t test.
ategorical data were analyzed using the Fisher exact test.
p value of0.05 was considered significant. The STATA
ersion 8.0 (StataCorp, College Station, Texas) program
as used to calculate binomial 95% confidence intervals
CI) for response rates and adverse event rates. Time-to-
vent curves (Kaplan-Meier analysis) were constructed us-
ng ibutilide conversion data to estimate the rate of success-
ul ibutilide conversion over time. Column charting was
sed to illustrate the difference in mean QTC interval
analyzed by paired Student t test) before and after ibutilide.
ESULTS
atient characteristics. A total of 71 patients (56.3% male,
4  14 years old) were studied. Forty-eight patients
67.6%) presented for cardioversion of AF and 23 patients
32.4%) for AFL. The mean and median durations of the
rrhythmia episode were 25  48 days and 2 days, respec-
ively (range: 1 to 240 days). The mean and median
urations of arrhythmia history were 4.4  6.4 years and 2
ears, respectively. Sixty-five patients (91.5%) had normal
V systolic function. The LVEF of the six patients with
epressed function ranged between 40% and 45%. These
atients had no history or signs of either active ischemic
eart disease or congestive heart failure, and they were
eemed safe to receive ibutilide infusion.
Forty-six patients (64.8%) were receiving propafenone
54  175 mg/day (300 to 900 mg/day), and 25 patients
35.2%) were treated with flecainide 226  65 mg/day (100
o 300 mg/day). The mean and median duration of class IC
gent therapy was 345  481 days and 106 days, respec-
ively. Twenty-one patients had been previously treated
ith another antiarrhythmic agent (quinidine [1 patient],
rocainamide [2 patients], sotalol [9 patients], amiodarone
8 patients], and dofetilide [1 patient]), and 4 patients had
een treated separately with both a class IA agent (quinidine
1 patient], procainamide [3 patients]) and sotalol. Table 1
ists baseline characteristics by arrhythmia type.
onversion rates. Twenty-three of 48 patients (47.9%;
5% CI, 33.3% to 62.8%) with AF converted to SR after
butilide with a mean conversion time of 25  14 min.
eventeen of 23 patients (73.9%; 95% CI, 51.6% to 89.8%)
ith AFL converted to SR after ibutilide with a meanonversion time of 20 12 min. Of the 42 patients that did bot convert after 30 min, 27 (64.3%) were observed beyond
0 min. Figure 2 shows the time-to-event curves for both
atients with AF and AFL. Most conversions for both AF
nd AFL patients occurred within 30 min of ibutilide
nitiation, but conversion continued to occur beyond 30
in. All 31 patients who did not convert with ibutilide had
uccessful and uneventful electrical cardioversions. No pa-
ient had termination of ibutilide infusion for either ven-
ricular dysrhythmia or excessive QT prolongation.
For the study population as a whole, there was no
tatistical difference in the ibutilide conversion rate between
able 1. Baseline Characteristics by Arrhythmia Type
AF
(n  48)
AFL
(n  23)
emographics
Age, yrs 64 16 65  8
Male 19 (39.6) 15 (65.2)
linical data
Arrhythmia duration*, days 32 54 11  27
Arrhythmia history, yrs 4.3  5.3 4.6  8.3
LVEF, 50% 44 (91.7) 21 (91.3)
ssociated diagnoses
Hypertension 13 (27.1) 10 (43.5)
COPD 1 2
Previous PE 2 0
Diabetes 0 2
CAD 1 0
Dilated CM 1 0
Hyperthyroidism 1 0
ntiarrhythmic agents
Propafenone 32 (66.7) 14 (60.9)
Flecainide 16 (33.3) 9 (39.1)
Therapy duration†, days 346  543 340  304
VN blocking agents
Any agent‡ 24 (50.0) 8 (34.8)
Beta-blocker 16 (33.3) 1 (4.3)
Calcium-channel blocker 5 (10.4) 5 (21.7)
Digoxin 4 (8.3) 3 (13.0)
Duration of arrhythmic episode for which patient presents for cardioversion;
Duration of class IC agent therapy before cardioversion; ‡One patient in each group
as receiving multiple agents. Data are presented as n (%) or mean  SD.
AF  atrial fibrillation; AFL  atrial flutter; AVN  atrioventricular node; CAD
coronary artery disease; CM  cardiomyopathy; COPD  chronic obstructive
ulmonary disease; LVEF  left ventricular ejection fraction; PE  pulmonary
mbolism.
igure 2. Time-to-event curves showing the estimated rate of ibutilide
onversions during the 60-min observation period after ibutilide initiation,
y arrhythmia type. AF  atrial fibrillation; AFL  atrial flutter.
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August 18, 2004:864–8 Cardioversion With Ibutilide and Class IC Agentshose with arrhythmia duration of 1 day (n  33) and
hose with arrhythmia duration of1 day (60.6% vs. 54.1%,
 0.378). Likewise, there was no statistical difference in
he ibutilide conversion rate between those with arrhythmia
uration of 7 days (n  42) and those with arrhythmia
uration of 7 days (61.9% vs. 50.0%, p  0.230). In
atients with AF, however, there was a trend toward a
igher ibutilide conversion rate in those with arrhythmia
uration 7 days (n  27) than in with those with
rrhythmia duration 7 days (59.3% vs. 33.3%, p  0.067)
nd, similarly, a higher conversion rate in those with
rrhythmia duration 1 day (n  21) than in those with
uration 1 day (61.9% vs. 37.0%, p  0.078). The only
ariable that clearly predicted success of ibutilide conversion
y univariate analysis was presence of AFL (Table 2).
ffect of ibutilide on ECG. Overall, there was a statisti-
ally significant increase in QT interval (352 55 ms to 439
62 ms, p 0.001) and QTC interval (442 61 ms to 462
59 ms, p  0.006) (Fig. 3) after ibutilide. The difference
n QTC interval before and after ibutilide was significant in
atients with AF (453 57 ms vs. 478 60 ms, p 0.004)
ut was not of statistical significance in patients with AFL
418  61 ms vs. 433  46 ms, p  0.252). Overall, the
ean QTC interval change was 20  54 ms.
dverse effects of ibutilide. Two patients (2.8%; 95% CI,
.3% to 9.8%) developed significant ventricular dysrhyth-
ias after conversion to SR after ibutilide infusion. A
2-year-old woman had frequent episodes of non-sustained
olymorphous ventricular tachycardia after electrical con-
ersion to sinus bradycardia (50 beats/min) that was asso-
iated with QT prolongation (500 ms). The dysrhythmia
as effectively suppressed with magnesium infusion. A
able 2. Predictors of Ibutilide Cardioversion Success by
nivariate Analysis
Conversion
(n  40)
No Conversion
(n  31) p Value
ge, yrs 63  15 66  12 0.356
ale 22 (55.0) 18 (58.1) 0.494
VEF, 50% 34 (85.0) 31 (100.0) 0.027*
ypertension 13 (32.5) 10 (32.3) 0.594
ropafenone use 28 (70.0) 18 (58.1) 0.213
VN blocker use 18 (45.0) 14 (45.2) 0.589
FL 17 (42.5) 6 (19.4) 0.034
rrhythmia duration,
days
22  46 30  51 0.462
rrhythmia duration,
1 day
20 (50.0) 14 (45.2) 0.435
rrhythmia duration,
7 days
26 (65.0) 17 (54.8) 0.266
F duration†, 1 day 11 (47.8) 8 (32.0) 0.205
F duration†, 7 days 15 (65.2) 11 (44.0) 0.118
aseline HR, beats/min 107 25 99  23 0.193
aseline QTc, ms 437 66 452  53 0.302
Tc increase, ms 12  52 33  55 0.144
More patients with normal left ventricular ejection fraction (LVEF) in nonconvert-
rs; †n  48, patients with AF. Data are expressed as n (%) or mean  SD.
AF atrial fibrillation; AFL atrial flutter; AVN atrioventricular node; HR
eart rate; LVEF  left ventricular ejection fraction; QTc  corrected QT interval.2-year-old woman presented with AF and rapid ventricu- car rate and was treated with propafenone, beta-blocker, and
igoxin. She developed sustained torsade de pointes after
butilide conversion to profound sinus bradycardia (28
eats/min) with marked QT-interval prolongation (600 ms)
nd was successfully treated with electrical cardioversion.
he continued to have non-sustained polymorphous ven-
ricular tachycardia after conversion despite magnesium and
soproterenol infusions, but she eventually responded to
opamine infusion. Both women had normal baseline QT
ntervals (360 and 320 ms, respectively), had normal LV
unction, and were subsequently confirmed to have sinus
ode dysfunction. Another patient developed a reversible
omplete right bundle branch block (QRS duration: 160
s) during and for several hours after ibutilide infusion
ithout apparent clinical consequence.
ISCUSSION
fficacy of combined ibutilide and class IC agent. Three
arge randomized placebo-controlled clinical trials (9–11)
stablished the efficacy of ibutilide and found 90-min (from
butilide initiation) conversion rates of 29%, 31%, and 28%
or AF and 38%, 63%, and 61% for AFL. Other random-
zed studies (3–5) compared ibutilide with other antiar-
hythmic agents and found 60- to 90-min ibutilide conver-
ion rates of 32% to 51% for AF and 64% to 76% for AFL.
n the only report that used ibutilide in combination with
nother antiarrhythmic agent, the 30-min conversion rate in
atients receiving concomitant amiodarone therapy was
bserved to be 39% for AF and 54% for AFL (12).
Although direct comparisons among studies with differ-
ng design cannot be made, ibutilide conversion rates in this
tudy appear to be in the range of most reports. Further-
ore, because the observation time in our study (30 to 60
in from ibutilide initiation) was shorter than what was
sed in most previous reports, the conversion rates that we
ound may underestimate the overall efficacy of therapy.
lthough the majority of conversions in our study occurred
ithin 30 min, continued conversions between 30 and 60
in (Fig. 2) suggest that there might have been higher
Figure 3. Change in overall corrected QT interval after ibutilide infusion.onversion rates if all patients were observed for a full hour
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bserved beyond 30 min).
afety of combined ibutilide and class IC agent. In the
hree major randomized placebo-controlled clinical trials,
he occurrences of sustained torsade de pointes were 2.4%,
.7%, and 2.3% (9–11). A meta-analysis of five studies (586
atients) found the occurrence of sustained torsade de
ointes with ibutilide to be 1.7% (13). Again, although a
irect comparison cannot be made, the risk of sustained
orsade de pointes in this study appears similar to that of
revious reports. The single occurrence of sustained torsade
e pointes in this study was in the setting of profound sinus
ode suppression after conversion, and it emphasizes the
mportance of assessing the presence of sinus node dysfunc-
ion before the use of ibutilide and avoiding overly aggres-
ive heart rate control immediately before cardioversion.
ttenuation of ibutilide-induced QTC prolongation.
ose-dependent mean increase in QTC interval after ibuti-
ide infusion has been reported in the range of 47 to 90 ms
10,11,14). Mean ibutilide-induced QTC interval prolonga-
ion was attenuated (20  54 ms), but without decrease in
butilide efficacy, in our study. This attenuation of ibutilide-
nduced QT prolongation suggests that class IC agents
lock slow inward INa in addition to fast INa.
tudy limitations. Because this study was not placebo-
ontrolled, the efficacy beyond that of placebo is not known.
he observed safety of ibutilide use in this study may have been
nfluenced by the nature of the study population. Because class
C agents are not used in patients with significant structural
eart disease, the study inherently selected patients with a
ower risk of proarrhythmia. In addition, 25 patients had been
reviously treated with either a class IA and/or class III
ntiarrhythmic agent without developing sustained torsade de
ointes, perhaps suggesting a lower susceptibility to proar-
hythmia in these patients. Insufficient power may explain the
nability to find variables other than arrhythmia type that
redicted conversion success.
eprint requests and correspondence: Dr. Melvin M. Schein-
an, Section of Cardiac Electrophysiology, University of
alifornia, San Francisco, 500 Parnassus Avenue, MU-East 4S,
ox 1354, San Francisco, California 94143-1354. E-mail:
cheinman@medicine.ucsf.edu.EFERENCES
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